851376-80-2

Usage

Uses

Used in Pharmaceutical Industry:
2,3,4,5,7,8-HEXAHYDRO-3-OXO-PYRAZOLO[3,4-D]AZEPINE-6(1H)-CARBOXYLIC ACID, T-BUTYL ESTER is used as a chemical intermediate for the development of new therapeutic agents. Its capacity to bind with specific receptors makes it a promising candidate for the creation of medications targeting various medical conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2,3,4,5,7,8-HEXAHYDRO-3-OXO-PYRAZOLO[3,4-D]AZEPINE-6(1H)-CARBOXYLIC ACID, T-BUTYL ESTER serves as a key component in the synthesis of novel compounds with potential pharmacological activity. Its structural features allow for the exploration of new drug discovery avenues and the enhancement of existing therapeutic strategies.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 141642-82-2 5-oxo-azepane-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 

Downstream Products

• 851376-81-3 1-benzyl-3-oxo-2,3,4,5,7,8-hexahydro-1H-1,2,6-triaza-azulene-6-carboxylic acid tert-butyl ester 
• 1190897-46-1 C₁₄H₁₇N₃O 
• 1190897-41-6 C₁₄H₁₇N₃O 

Relevant academic research and scientific papers

Discovery of β-Arrestin Biased Ligands of 5-HT7R

Though many studies have been published about therapeutic potentials of selective 5-HT7R ligands, there have been few biased ligands of 5-HT7R. The development of potent and selective biased ligands of 5-HT7R would be of great help in understanding the relationship between pharmacological effects and G protein/β-arrestin signaling pathways of 5-HT7R. In order to identify 5-HT7R ligands with biased agonism, we designed and synthesized a series of tetrahydroazepine derivatives 1 and 2 with arylpyrazolo moiety or arylisoxazolo moiety. Through several biological evaluations such as binding affinity, selectivity profile, and functions in G protein and β-arrestin signaling pathways, 3-(4-chlorophenyl)-1,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepine 1g was discovered as the β-arrestin biased ligand of 5-HT7R. In an electroencephalogram (EEG) test, 1g increased total non-rapid eye movement (NREM) sleep time and decreased total rapid eye movement (REM) sleep time.

Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence

A range of heterocycle fused azepines were synthesized in order to find a CNS penetrant, selective 5-HT2C agonist for the treatment of incontinence. The pyridazo-azepines such as compound 11 were shown to be potent 5-HT2C agonists and have potential for CNS penetration and good in vitro ADME properties but lacked selectivity against 5-HT2B. Fusing a further heterocycle gave the selective triazolopyrimido-azepines. An example of this series, compound 36, was shown to be potent, selective, metabolically stable in vitro and efficacious in an in vivo model of stress urinary incontinence.

FUSED HETEROCYCLIC COMPOUNDS

Certain fused pyrrole- and pyrazole-containing heterocyclic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases.